GNTA Genenta Science Quarterly EPS earnings growth

Official company branding of genenta.com (GNTA)

Future revenues for Genenta Science S.p.A. (GNTA) rely on the sale of gene modification methods for treating brain tumors. Historical quarterly EPS growth reflects the current dynamics of this process, with the latest mark standing at 48.40. The business's success is tied to the safety of interferon delivery and patient survival rates. Meanwhile, the company strictly adheres to biomaterial disposal regulations within its laboratories.

Genenta Science (GNTA) Year-over-year earnings per share growth for the last twelve months: for the period 07/04/2022 - 11/04/2026

genenta.com (GNTA) - metric breakdowns and financial figures

- share price and expert price forecast:
Stock Price Genenta|GNTA - Consensus Target
- market capitalization data:
Market Capitalization Genenta|GNTA - Total Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Genenta Science|GNTA - Company Book Value|Market Value to Book Value Ratio genenta.com|GNTA - Aggregate Company Assets
- company liabilities and liquidity data:
Total Debt to Equity Ratio Genenta Science S.p.A.|GNTA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Genenta Science SpA|GNTA - Company Total Indebtedness|Debts to Book Capitalization Genenta|GNTA - Long-Term Debt|Company Short-Term Debt Genenta Science|Quick Ratio genenta.com
- earnings and market multiples details:
GNTA - Company Net Income|Future Profit Genenta Science S.p.A.|GNTA - Company Value to Net Income|Projected Price to Earnings genenta.com|GNTA - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Genenta Science S.p.A.|GNTA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Genenta Science|GNTA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months genenta.com|GNTA - Earnings per share increase in current year|Earnings growth forecast for next year Genenta Science S.p.A.
- sales volume and revenue information:
GNTA - Revenue and Sales Volume|Company Projected Revenue Genenta Science|GNTA - Price-to-Sales Ratio|Forward Price-to-Revenue Multiple Genenta
Fundamental company analysis:Genenta Science SpA - GNTA
Finished products of Genenta Science S.p.A.

High development costs for cancer cell therapies make Genenta Science S.p.A. (GNTA) sensitive to capitalization efficiency, as reflected in the current quarterly EPS growth rate. This indicator measures the dynamics of net income per share, allowing investors to assess the actual speed of innovation monetization and business resilience amid fierce competition in the rare tumor market.

Analysis of competing companies

LEGN: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Sana Bio|AUTL (Autolus Therapeutics PLC) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months allogene.com ALLO|Year-over-year earnings per share growth for the last twelve months Cartesian Therapeutics, Inc. (RNAC)|Year-over-year earnings per share growth for the last twelve months CLLS (Cellectis SA)|Year-over-year earnings per share growth for the last twelve months Caribou Bio CRBU|Year-over-year earnings per one share growth for the last 12 months TIL|IPSC: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months JSPR (jaspertherapeutics.com)|SNTI: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Adaptimmune Therapeutics plc ADAP|CERO (CERo Therapeutics Holdings, Inc.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months alaunos.com TCRT|Year-over-year earnings per share growth for the last twelve months Achilles Tx (ACHL)|CARGO Therapeutics - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth PSTX (Poseida Corp)|2seventy Bio (TSVT) - Earnings per share growth in annualized terms for the last twelve months|GRCL: Year-over-year net earnings per share growth for the last 12 months